Sana Biotechnology (NASDAQ:SANA) Shares Down 3.4%

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price fell 3.4% on Wednesday . The stock traded as low as $5.16 and last traded at $5.17. 467,107 shares traded hands during trading, a decline of 82% from the average session volume of 2,635,602 shares. The stock had previously closed at $5.35.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on SANA shares. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Sana Biotechnology in a research note on Thursday, May 9th. Rodman & Renshaw assumed coverage on shares of Sana Biotechnology in a research report on Wednesday, June 26th. They issued a “buy” rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Sana Biotechnology Price Performance

The stock’s fifty day moving average is $7.57 and its 200-day moving average is $7.43. The stock has a market capitalization of $1.16 billion, a P/E ratio of -3.41 and a beta of 1.46.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). On average, research analysts expect that Sana Biotechnology, Inc. will post -1.15 EPS for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Hedge funds have recently made changes to their positions in the stock. Capital World Investors raised its position in Sana Biotechnology by 255.8% in the first quarter. Capital World Investors now owns 5,449,035 shares of the company’s stock worth $54,490,000 after purchasing an additional 3,917,728 shares in the last quarter. Vanguard Group Inc. raised its position in Sana Biotechnology by 24.1% in the first quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock worth $121,552,000 after purchasing an additional 2,358,089 shares in the last quarter. PFM Health Sciences LP raised its position in Sana Biotechnology by 51.4% in the fourth quarter. PFM Health Sciences LP now owns 1,883,337 shares of the company’s stock worth $7,684,000 after purchasing an additional 639,198 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Sana Biotechnology in the third quarter worth about $2,091,000. Finally, Baillie Gifford & Co. raised its position in Sana Biotechnology by 5.0% in the first quarter. Baillie Gifford & Co. now owns 10,656,279 shares of the company’s stock worth $106,563,000 after purchasing an additional 506,262 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.